Attend the Geneva Vaccine Forum 2008 to:

• Gain insights into the scale of public health threats and potential markets for the vaccine industry on a region-by-region basis
  
  
• Assess the ongoing funding strategies and priorities of major public sector and NGO bodies including the European Commission, the US Government and the Bill & Melinda Gates Foundation
  
  
• Find out how the vaccine industry can best demonstrate the value of novel vaccines to regulators, payers and patients moving forwards
  
  
• Update your understanding of how to navigate issues raised by a lack of regulatory harmonisation between the US and Europe
  
  
• Evaluate the pros and cons of incorporating a novel adjuvant into your vaccine R&D strategy
  
  
• Hone your global market access and development strategies through lessons learnt by the major vaccine companies
  
  
• Inform your ongoing corporate development strategy through detailed analysis of recent and current partnering and licensing trends between large and small vaccine companies
  
  
• Analyse the latest clinical data from leading vaccine candidates against nosocomial infections
  
  
• Discover how leading vaccine companies with novel adjuvants in development are addressing challenges in demonstrating both safety and immunogenicity
  
  
• Discuss solutions to the remaining challenges in the development of DNA vaccines and viral vector systems with key industry players and regulators
  
  
• Examine ongoing clinical development strategies for therapeutic vaccines against a range of infectious and non-infectious disease targets
  
  
• Learn about novel delivery and stabilisation technologies with the potential to remove the cold chain
  
  
• Debate possible future pathways for AIDS vaccine R&D
  
  
• Compare and contrast the potential of various novel manufacturing technologies in development
  
  
• NETWORK with senior level representatives of all the major big pharma and biotech industry players, as well as the regulators and other key public sector stakeholders, payers, investors and analysts.
  
  Click here for the latest programme information.
  

Top^